NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
| NCT ID | NCT03452774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massive Bio, Inc. |
| Condition | Cancer, Metastatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2038-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2018-01-01 with a primary completion date of 2038-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Eligibility Criteria
Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others. These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform * Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient Exclusion Criteria: * ECOG PS \> 2; * Abnormal organ function; * Hospice enrollment
Contact & Investigator
Selin Kurnaz, PhD
PRINCIPAL INVESTIGATOR
Massive Bio, Inc.
Frequently Asked Questions
Who can join the NCT03452774 clinical trial?
This trial is open to participants of all sexes, studying Cancer, Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03452774 currently recruiting?
Yes, NCT03452774 is actively recruiting participants. Contact the research team at fevans@massivebio.com for enrollment information.
Where is the NCT03452774 trial being conducted?
This trial is being conducted at Birmingham, United States, Mobile, United States, Scottsdale, United States, Little Rock, United States and 11 additional locations.
Who is sponsoring the NCT03452774 clinical trial?
NCT03452774 is sponsored by Massive Bio, Inc.. The principal investigator is Selin Kurnaz, PhD at Massive Bio, Inc.. The trial plans to enroll 50,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.